Adult growth hormone deficiency
- PMID: 22029024
- PMCID: PMC3183535
- DOI: 10.4103/2230-8210.84865
Adult growth hormone deficiency
Abstract
Adult growth hormone deficiency (AGHD) is being recognized increasingly and has been thought to be associated with premature mortality. Pituitary tumors are the commonest cause for AGHD. Growth hormone deficiency (GHD) has been associated with neuropsychiatric-cognitive, cardiovascular, neuromuscular, metabolic, and skeletal abnormalities. Most of these can be reversed with growth hormone therapy. The insulin tolerance test still remains the gold standard dynamic test to diagnose AGHD. Growth hormone is administered subcutaneously once a day, titrated to clinical symptoms, signs and IGF-1 (insulin like growth factor-1). It is generally well tolerated at the low-doses used in adults. Pegylated human growth hormone therapy is on the horizon, with a convenient once a week dosing.
Keywords: Adult growth hormone deficiency; growth hormone; growth hormone deficiency; hypopituitarism; panhypopituitarism.
Conflict of interest statement
References
-
- Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285–8. - PubMed
-
- Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75–81. - PubMed
-
- Smith PE. The disabilities caused by hypophysectomy and their repair. J Am Med Assoc. 1927;88:158–61.
-
- Borchardt Die Hypophysenglykosurie und ihre Beziehun- gen zum Diabetes bei der Akromegalie. Z Klin Med L. 1908;66:332–48.
LinkOut - more resources
Full Text Sources
Miscellaneous
